SEC Filing Summary: BioTime, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2008. The registrant is BioTime, Inc. (Note: The input metadata referenced "Lineage Cell Therapeutics," but the filing text explicitly identifies the company as BioTime, Inc.). BioTime is a biomedical organization focused on synthetic plasma expanders (Hextend), organ preservation solutions, and regenerative medicine via its subsidiary, Embryome Sciences, Inc. The company operates with a significant accumulated deficit and relies on licensing fees, royalties, and debt financing.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Total Revenues | $426,931 | $1,218,512 | - |
| Net Loss | $(1,077,194) | $(2,215,935) | - |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.09) | - |
| Cash and Cash Equivalents | - | - | $52,082 |
| Total Current Assets | - | - | $94,042 |
| Total Current Liabilities | - | - | $3,964,526 |
| Working Capital | - | - | $(3,870,484) |
| Lines of Credit Payable | - | - | $2,645,577 |
| Accumulated Deficit | - | - | $(46,060,432) |
Cash Flow (Nine Months Ended Sep 30, 2008):
- Net cash used in operating activities: $(1,092,561)
- Net cash used in investing activities: $(861,390) (Includes $750,000 royalty fee payments)
- Net cash provided by financing activities: $1,936,532 (Primarily borrowings under lines of credit)
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 85% for the three months ended September 30, 2008, compared to the same period in 2007 ($426,931 vs. $231,159). Royalty revenue specifically surged 86% to $341,391, driven by increased sales of Hextend to the U.S. Armed Forces.
- Expense Increases: Operating expenses rose significantly. Research and Development (R&D) expenses increased 222% ($548,478 vs. $170,382) and General and Administrative (G&A) expenses increased 266% ($792,306 vs. $216,443) for the three-month period. These increases are attributed to the expansion into stem cell research and regenerative medicine.
- Debt Expansion: Lines of credit payable increased from $716,537 at year-end 2007 to $2,645,577 at September 30, 2008, reflecting increased borrowing to fund operations.
- Asset Acquisition: The company recorded $820,976 in "Advance license fee and others," a significant increase from $20,976 in the prior year, due to new licensing agreements for stem cell technology.
Outlook, Risks, and Management Commentary
Liquidity and Going Concern: Management explicitly states that the financial statements are prepared assuming the company will continue as a going concern. With only $52,082 in cash and negative working capital of nearly $3.9 million, BioTime requires additional capital to continue operations. The company is actively seeking equity financing, new license agreements, and extensions of its credit lines.
Strategic Shift: The company has pivoted toward regenerative medicine through its subsidiary, Embryome Sciences. Significant capital was deployed in 2008 to acquire licenses from Advanced Cell Technology (ACT) and Wisconsin Alumni Research Foundation (WARF) to develop stem cell products.
Debt Maturity and Conversion: A major revolving line of credit matured on November 15, 2008. Subsequent to the reporting period (November 2008), the company amended this agreement to extend the maturity to April 15, 2009, and increase the limit to $3.5 million. Lenders have the option to convert debt to equity.
Risks: Key risks include the inability to secure additional financing, the uncertainty of clinical trial results for PentaLyte, regulatory approval hurdles, and the dilution of shareholders from potential equity raises or debt conversions.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $52,082 cash balance against the monthly burn rate and the status of the November 2008 credit line extension.
- Debt Conversion Terms: Review the specific conversion prices ($1.25–$1.50 for BioTime shares) and the volume of debt converted to equity in November 2008 to assess dilution impact.
- Revenue Recognition Timing: Confirm the lag between sales and royalty recognition, as the company recognizes revenue when reports are received, not when sales occur. Note that $231,896 in royalties received in October 2008 relates to Q3 sales.
- License Obligations: Assess the future cash outflow requirements for the new stem cell licenses (ACT, WARF) and the royalty obligations to Summit Pharmaceuticals.
- Going Concern Status: Monitor subsequent filings for evidence of successful capital raises or the potential need to curtail operations if financing is not secured.